ER stress and virulence of Aspergillus fumigatus

烟曲霉的内质网应激和毒力

基本信息

  • 批准号:
    7367672
  • 负责人:
  • 金额:
    $ 35.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-12-01 至 2012-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Aspergillus fumigatus is an important opportunistic fungal pathogen that has become the leading infectious mould of immunocompromised patients. Despite some advances in therapy, invasive aspergillosis continues to have a poor outcome, emphasizing the need for more information on fungal pathways that are essential to the growth of the organism in vivo. A. fumigatus secretes tremendous quantities of extracellular proteins as part of its normal saprophytic lifestyle, which places it at high risk for protein unfolding and endoplasmic reticulum (ER) stress. The unfolded protein response (UPR) counters this stress by upregulating the expression of genes involved in protein folding, secretion and degradation. In this grant, we provide preliminary data that A. fumigatus relies heavily upon the UPR to support the secretory activity that it needs to survive ER stress and acquire nutrients from host tissue. Secondly, we demonstrate that loss of UPR function exhibits potent synergism with existing antifungal drugs against A. fumigatus. Using mutants of the UPR and the related ER- associated degradation pathway (ERAD), we propose to validate ER stress responses as a therapeutic target for aspergillosis, and to gain insight into the key components of the response. The following specific Aims are proposed: Aim I will test the hypothesis that the UPR is essential for the growth of A. fumigatus under conditions of ER stress, and that it contributes to the ability of the organism to cause disease in vivo. Aim II will test the hypothesis that ERAD is also required to sustain growth under conditions of ER stress, and that it works in concert with the UPR to support the virulence of the organism in vivo. Aim III will use a genome-wide approach to identify novel components of the A. fumigatus ER stress response by testing the hypothesis that the response of A. fumigatus to ER stress involves specific changes in the transcription and translation of a subset of mRNAs. These studies have the potential to identify novel targets for the treatment of aspergillosis, and have broader implications for increasing the antifungal susceptibility profile of fungal species that are intrinsically resistant to existing antifungals.
描述(由申请人提供):曲曲霉是一种重要的机会性真菌病原体,已成为免疫功能低下患者的主要感染模具。尽管在治疗方面取得了一些进步,但侵入性曲霉病仍会取得较差的结果,强调需要更多有关对体内生物生长至关重要的真菌途径的信息。 A. fumigatus分泌大量的细胞外蛋白,这是其正常的腐生生活方式的一部分,它使其具有蛋白质展开和内质网(ER)胁迫的高风险。展开的蛋白质反应(UPR)通过上调涉及蛋白质折叠,分泌和降解的基因的表达来抵消这种应激。在这笔赠款中,我们提供了烟曲霉的初步数据,严重依赖UPR来支持其生存的分泌活性,以使ER应力生存并从宿主组织中获取营养。其次,我们证明了UPR功能的丧失与现有的抗真菌药物相对于烟曲霉表现出有效的协同作用。使用UPR的突变体和相关的降解途径(ERAD),我们建议验证ER应力反应作为曲霉病的治疗靶标,并深入了解反应的关键成分。提出了以下具体目的:目标我将检验以下假设:在ER应激条件下,UPR对于烟曲霉的生长至关重要,并且它有助于生物体在体内引起疾病的能力。 AIM II将检验以下假设:在ER压力条件下还需要Erad来维持增长,并且它与UPR协同工作以支持体内生物体的毒力。 AIM III将使用全基因组的方法来鉴定烟曲霉的应激响应的新成分,即通过检验以下假设:烟曲霉对ER应激的响应涉及mRNA子集的转录和翻译的特定变化。这些研究有可能识别用于治疗曲霉病的新靶标,并且对增加对现有抗真菌性物质抗性的真菌物种的抗真菌易感性概况具有更大的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID S ASKEW其他文献

DAVID S ASKEW的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID S ASKEW', 18)}}的其他基金

Aspergillus fumigatus infection and fibrosis
烟曲霉感染和纤维化
  • 批准号:
    10367232
  • 财政年份:
    2021
  • 资助金额:
    $ 35.1万
  • 项目类别:
Aspergillus fumigatus infection and fibrosis
烟曲霉感染和纤维化
  • 批准号:
    10685373
  • 财政年份:
    2021
  • 资助金额:
    $ 35.1万
  • 项目类别:
ER stress and calcium in host adaptation of A. fumigatus
烟曲霉宿主适应中的内质网应激和钙
  • 批准号:
    9761966
  • 财政年份:
    2016
  • 资助金额:
    $ 35.1万
  • 项目类别:
ER stress and calcium in host adaptation of A. fumigatus
烟曲霉宿主适应中的内质网应激和钙
  • 批准号:
    9979741
  • 财政年份:
    2016
  • 资助金额:
    $ 35.1万
  • 项目类别:
Translational repression & Aspergillus fumigatus virulence
转化抑制
  • 批准号:
    8681609
  • 财政年份:
    2014
  • 资助金额:
    $ 35.1万
  • 项目类别:
Translational repression & Aspergillus fumigatus virulence
转化抑制
  • 批准号:
    8792613
  • 财政年份:
    2014
  • 资助金额:
    $ 35.1万
  • 项目类别:
High-density lipoprotein and A. fumigatus pathogenesis
高密度脂蛋白与烟曲霉发病机制
  • 批准号:
    8709034
  • 财政年份:
    2013
  • 资助金额:
    $ 35.1万
  • 项目类别:
Translation state array analysis in Aspergillus fumigatus
烟曲霉翻译态阵列分析
  • 批准号:
    7561654
  • 财政年份:
    2008
  • 资助金额:
    $ 35.1万
  • 项目类别:
Translation state array analysis in Aspergillus fumigatus
烟曲霉翻译态阵列分析
  • 批准号:
    7470253
  • 财政年份:
    2008
  • 资助金额:
    $ 35.1万
  • 项目类别:
ER stress and virulence of Aspergillus fumigatus
烟曲霉的内质网应激和毒力
  • 批准号:
    7739483
  • 财政年份:
    2007
  • 资助金额:
    $ 35.1万
  • 项目类别:

相似海外基金

Examining the importance of folate biosynthetic enzymes in infectious fungi
检查叶酸生物合成酶在传染性真菌中的重要性
  • 批准号:
    10308098
  • 财政年份:
    2020
  • 资助金额:
    $ 35.1万
  • 项目类别:
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi
病原真菌 Prp8 内含肽剪接抑制剂的高通量筛选
  • 批准号:
    10319642
  • 财政年份:
    2018
  • 资助金额:
    $ 35.1万
  • 项目类别:
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi
病原真菌 Prp8 内含肽剪接抑制剂的高通量筛选
  • 批准号:
    10382470
  • 财政年份:
    2018
  • 资助金额:
    $ 35.1万
  • 项目类别:
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer
逆转录病毒复制载体介导的卵巢癌基因治疗
  • 批准号:
    9754592
  • 财政年份:
    2017
  • 资助金额:
    $ 35.1万
  • 项目类别:
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer
逆转录病毒复制载体介导的卵巢癌基因治疗
  • 批准号:
    9384558
  • 财政年份:
    2017
  • 资助金额:
    $ 35.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了